annual CFF:
$1.27B+$10.44B(+113.82%)Summary
- As of today (May 29, 2025), NVO annual cash flow from financing activities is $1.27 billion, with the most recent change of +$10.44 billion (+113.82%) on December 31, 2024.
- During the last 3 years, NVO annual CFF has risen by +$5.32 billion (+131.24%).
- NVO annual CFF is now at all-time high.
Performance
NVO Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$768.50M-$4.64B(-85.79%)Summary
- As of today (May 29, 2025), NVO quarterly cash flow from financing activities is $768.50 million, with the most recent change of -$4.64 billion (-85.79%) on March 31, 2025.
- Over the past year, NVO quarterly CFF has increased by +$4.61 billion (+120.00%).
- NVO quarterly CFF is now -85.79% below its all-time high of $5.41 billion, reached on December 31, 2024.
Performance
NVO quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$5.88B+$4.61B(+363.85%)Summary
- As of today (May 29, 2025), NVO TTM cash flow from financing activities is $5.88 billion, with the most recent change of +$4.61 billion (+363.85%) on March 31, 2025.
- Over the past year, NVO TTM CFF has increased by +$15.92 billion (+158.56%).
- NVO TTM CFF is now at all-time high.
Performance
NVO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NVO Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +113.8% | +120.0% | +158.6% |
| 3 y3 years | +131.2% | +126.6% | +227.9% |
| 5 y5 years | +123.8% | +138.5% | +211.8% |
NVO Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +113.8% | -85.8% | +120.0% | at high | +158.6% |
| 5 y | 5-year | at high | +113.8% | -85.8% | +120.0% | at high | +158.6% |
| alltime | all time | at high | +113.8% | -85.8% | +120.0% | at high | +158.6% |
NVO Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $768.50M(-85.8%) | $5.88B(+363.8%) |
| Dec 2024 | $1.27B(-113.8%) | $5.41B(-297.3%) | $1.27B(-122.8%) |
| Sep 2024 | - | -$2.74B(-212.2%) | -$5.56B(-2.6%) |
| Jun 2024 | - | $2.44B(-163.6%) | -$5.72B(-43.1%) |
| Mar 2024 | - | -$3.84B(+169.9%) | -$10.04B(+9.5%) |
| Dec 2023 | -$9.17B(+24.9%) | -$1.42B(-50.8%) | -$9.17B(+0.6%) |
| Sep 2023 | - | -$2.89B(+53.8%) | -$9.11B(+14.4%) |
| Jun 2023 | - | -$1.88B(-36.8%) | -$7.96B(+7.2%) |
| Mar 2023 | - | -$2.97B(+117.3%) | -$7.43B(+1.2%) |
| Dec 2022 | -$7.34B(+81.0%) | -$1.37B(-21.4%) | -$7.34B(+39.4%) |
| Sep 2022 | - | -$1.74B(+29.4%) | -$5.27B(-1.0%) |
| Jun 2022 | - | -$1.35B(-53.4%) | -$5.32B(+15.8%) |
| Mar 2022 | - | -$2.89B(-508.6%) | -$4.60B(+13.3%) |
| Dec 2021 | -$4.06B(-17.9%) | $706.40M(-139.3%) | -$4.06B(-13.6%) |
| Sep 2021 | - | -$1.80B(+189.1%) | -$4.69B(-1.8%) |
| Jun 2021 | - | -$621.02M(-73.5%) | -$4.78B(-9.7%) |
| Mar 2021 | - | -$2.35B(-3534.5%) | -$5.29B(+7.1%) |
| Dec 2020 | -$4.94B(-7.1%) | $68.32M(-103.6%) | -$4.94B(-15.1%) |
| Sep 2020 | - | -$1.88B(+65.6%) | -$5.82B(+7.7%) |
| Jun 2020 | - | -$1.13B(-43.1%) | -$5.40B(+2.7%) |
| Mar 2020 | - | -$1.99B(+146.4%) | -$5.26B(-1.2%) |
| Dec 2019 | -$5.32B(-2.7%) | -$809.38M(-44.6%) | -$5.32B(+1.5%) |
| Sep 2019 | - | -$1.46B(+47.4%) | -$5.24B(-2.6%) |
| Jun 2019 | - | -$991.30M(-51.8%) | -$5.38B(+3.6%) |
| Mar 2019 | - | -$2.06B(+181.0%) | -$5.19B(-5.0%) |
| Dec 2018 | -$5.47B(+0.7%) | -$732.56M(-54.3%) | -$5.47B(+4.1%) |
| Sep 2018 | - | -$1.60B(+99.7%) | -$5.26B(-7.6%) |
| Jun 2018 | - | -$801.92M(-65.6%) | -$5.69B(-1.9%) |
| Mar 2018 | - | -$2.33B(+348.9%) | -$5.80B(+6.7%) |
| Dec 2017 | -$5.43B(-6.0%) | -$519.59M(-74.5%) | -$5.43B(-0.8%) |
| Sep 2017 | - | -$2.04B(+123.8%) | -$5.48B(+7.9%) |
| Jun 2017 | - | -$910.12M(-53.7%) | -$5.07B(-2.5%) |
| Mar 2017 | - | -$1.97B(+249.2%) | -$5.21B(-9.9%) |
| Dec 2016 | -$5.78B(+29.1%) | -$563.10M(-65.6%) | -$5.78B(-1.6%) |
| Sep 2016 | - | -$1.64B(+56.8%) | -$5.87B(+17.5%) |
| Jun 2016 | - | -$1.04B(-58.9%) | -$5.00B(+3.3%) |
| Mar 2016 | - | -$2.54B(+286.0%) | -$4.84B(+8.1%) |
| Dec 2015 | -$4.48B(-5.4%) | -$657.78M(-13.5%) | -$4.48B(-1.0%) |
| Sep 2015 | - | -$760.74M(-14.0%) | -$4.52B(+3.9%) |
| Jun 2015 | - | -$884.11M(-59.4%) | -$4.35B(-3.0%) |
| Mar 2015 | - | -$2.18B(+209.5%) | -$4.49B(-5.1%) |
| Dec 2014 | -$4.73B(+12.4%) | -$702.88M(+18.8%) | -$4.73B(+3.5%) |
| Sep 2014 | - | -$591.83M(-41.9%) | -$4.57B(+1.0%) |
| Jun 2014 | - | -$1.02B(-57.9%) | -$4.53B(-3.7%) |
| Mar 2014 | - | -$2.42B(+344.1%) | -$4.71B(+11.8%) |
| Dec 2013 | -$4.21B(+21.0%) | -$544.69M(-0.7%) | -$4.21B(+4.0%) |
| Sep 2013 | - | -$548.45M(-54.1%) | -$4.05B(+7.9%) |
| Jun 2013 | - | -$1.19B(-37.9%) | -$3.75B(-0.4%) |
| Mar 2013 | - | -$1.92B(+400.9%) | -$3.77B(+8.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$3.48B(+10.8%) | -$383.65M(+51.2%) | -$3.48B(-3.6%) |
| Sep 2012 | - | -$253.72M(-79.0%) | -$3.61B(-15.1%) |
| Jun 2012 | - | -$1.21B(-25.7%) | -$4.25B(+21.8%) |
| Mar 2012 | - | -$1.63B(+217.6%) | -$3.49B(+11.1%) |
| Dec 2011 | -$3.14B(+33.4%) | -$513.03M(-42.6%) | -$3.14B(+6.5%) |
| Sep 2011 | - | -$894.01M(+98.9%) | -$2.95B(+5.4%) |
| Jun 2011 | - | -$449.57M(-64.9%) | -$2.80B(+7.3%) |
| Mar 2011 | - | -$1.28B(+298.6%) | -$2.61B(+10.7%) |
| Dec 2010 | -$2.35B(+25.2%) | -$321.69M(-56.6%) | -$2.35B(+3.4%) |
| Sep 2010 | - | -$742.02M(+185.7%) | -$2.28B(+8.6%) |
| Jun 2010 | - | -$259.69M(-74.8%) | -$2.10B(-1.3%) |
| Mar 2010 | - | -$1.03B(+321.7%) | -$2.12B(+13.0%) |
| Dec 2009 | -$1.88B(+29.2%) | -$244.26M(-56.6%) | -$1.88B(+1.7%) |
| Sep 2009 | - | -$562.24M(+96.0%) | -$1.85B(+12.7%) |
| Jun 2009 | - | -$286.92M(-63.5%) | -$1.64B(+4.9%) |
| Mar 2009 | - | -$786.49M(+268.9%) | -$1.56B(+7.5%) |
| Dec 2008 | -$1.46B(+15.6%) | -$213.21M(-39.8%) | -$1.46B(-10.4%) |
| Sep 2008 | - | -$354.42M(+68.8%) | -$1.62B(-7.8%) |
| Jun 2008 | - | -$209.98M(-69.0%) | -$1.76B(+12.6%) |
| Mar 2008 | - | -$677.61M(+77.2%) | -$1.57B(+24.4%) |
| Dec 2007 | -$1.26B(+57.0%) | -$382.37M(-22.2%) | -$1.26B(+48.0%) |
| Sep 2007 | - | -$491.74M(+3599.5%) | -$850.45M(+10.4%) |
| Jun 2007 | - | -$13.29M(-96.4%) | -$770.16M(-4.2%) |
| Mar 2007 | - | -$370.90M(-1555.5%) | -$804.05M(+0.3%) |
| Dec 2006 | -$801.30M(+8.3%) | $25.48M(-106.2%) | -$801.30M(-9.6%) |
| Sep 2006 | - | -$411.45M(+772.0%) | -$886.08M(+44.7%) |
| Jun 2006 | - | -$47.18M(-87.2%) | -$612.34M(-22.4%) |
| Mar 2006 | - | -$368.15M(+520.8%) | -$789.25M(+6.6%) |
| Dec 2005 | -$740.21M(+27.4%) | -$59.30M(-56.9%) | -$740.21M(-6.9%) |
| Sep 2005 | - | -$137.71M(-38.5%) | -$795.32M(+3.6%) |
| Jun 2005 | - | -$224.09M(-29.8%) | -$767.92M(+18.4%) |
| Mar 2005 | - | -$319.12M(+178.9%) | -$648.77M(+11.7%) |
| Dec 2004 | -$581.00M(+59.0%) | -$114.41M(+3.7%) | -$581.00M(+24.5%) |
| Sep 2004 | - | -$110.30M(+5.1%) | -$466.59M(+31.0%) |
| Jun 2004 | - | -$104.94M(-58.2%) | -$356.29M(+41.8%) |
| Mar 2004 | - | -$251.34M | -$251.34M |
| Dec 2003 | -$365.44M(+88.7%) | - | - |
| Dec 2002 | -$193.64M(+70.7%) | - | - |
| Dec 2001 | -$113.45M(-57.4%) | - | - |
| Dec 2000 | -$266.45M(-861.5%) | - | - |
| Dec 1999 | $34.99M(-113.6%) | - | - |
| Dec 1998 | -$257.97M(-480.4%) | - | - |
| Dec 1997 | $67.81M(-144.7%) | - | - |
| Dec 1996 | -$151.76M(-54.0%) | - | - |
| Dec 1995 | -$330.04M(-454.3%) | - | - |
| Dec 1994 | $93.15M(-31.2%) | - | - |
| Dec 1993 | $135.48M(-6.3%) | - | - |
| Dec 1992 | $144.55M(-59.5%) | - | - |
| Dec 1991 | $356.99M(+426.2%) | - | - |
| Dec 1990 | $67.84M | - | - |
FAQ
- What is Novo Nordisk A/S annual cash flow from financing activities?
- What is the all time high annual CFF for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual CFF year-on-year change?
- What is Novo Nordisk A/S quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly CFF year-on-year change?
- What is Novo Nordisk A/S TTM cash flow from financing activities?
- What is the all time high TTM CFF for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM CFF year-on-year change?
What is Novo Nordisk A/S annual cash flow from financing activities?
The current annual CFF of NVO is $1.27B
What is the all time high annual CFF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual cash flow from financing activities is $1.27B
What is Novo Nordisk A/S annual CFF year-on-year change?
Over the past year, NVO annual cash flow from financing activities has changed by +$10.44B (+113.82%)
What is Novo Nordisk A/S quarterly cash flow from financing activities?
The current quarterly CFF of NVO is $768.50M
What is the all time high quarterly CFF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly cash flow from financing activities is $5.41B
What is Novo Nordisk A/S quarterly CFF year-on-year change?
Over the past year, NVO quarterly cash flow from financing activities has changed by +$4.61B (+120.00%)
What is Novo Nordisk A/S TTM cash flow from financing activities?
The current TTM CFF of NVO is $5.88B
What is the all time high TTM CFF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM cash flow from financing activities is $5.88B
What is Novo Nordisk A/S TTM CFF year-on-year change?
Over the past year, NVO TTM cash flow from financing activities has changed by +$15.92B (+158.56%)